Ionis Pharmaceuticals (IONS) Getting Somewhat Positive News Coverage, Analysis Shows

News coverage about Ionis Pharmaceuticals (NASDAQ:IONS) has trended somewhat positive recently, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ionis Pharmaceuticals earned a news impact score of 0.03 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.8362477896052 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

NASDAQ:IONS opened at $45.53 on Friday. The company has a debt-to-equity ratio of 1.59, a quick ratio of 5.33 and a current ratio of 5.38. Ionis Pharmaceuticals has a one year low of $39.07 and a one year high of $65.51. The company has a market cap of $5.71 billion, a P/E ratio of 569.13 and a beta of 2.63.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Friday, May 4th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.10. Ionis Pharmaceuticals had a negative net margin of 2.00% and a negative return on equity of 3.06%. The business had revenue of $144.40 million for the quarter, compared to the consensus estimate of $144.01 million. During the same period last year, the company earned $0.03 EPS. The firm’s revenue was up 24.7% compared to the same quarter last year. analysts expect that Ionis Pharmaceuticals will post -0.04 earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on IONS shares. Morgan Stanley reduced their price target on shares of Ionis Pharmaceuticals to $52.00 and set an “equal weight” rating on the stock in a research note on Monday, May 7th. Piper Jaffray Companies started coverage on shares of Ionis Pharmaceuticals in a research note on Wednesday, May 30th. They issued a “hold” rating and a $50.00 price target on the stock. Zacks Investment Research downgraded shares of Ionis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 10th. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 23rd. Finally, BidaskClub upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, April 12th. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $52.83.

In other news, Chairman Stanley T. Crooke sold 13,962 shares of the business’s stock in a transaction that occurred on Tuesday, April 17th. The shares were sold at an average price of $44.40, for a total value of $619,912.80. Following the transaction, the chairman now owns 56,714 shares in the company, valued at approximately $2,518,101.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Spencer R. Berthelsen sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 25th. The stock was sold at an average price of $42.30, for a total transaction of $634,500.00. Following the completion of the transaction, the director now owns 97,127 shares in the company, valued at approximately $4,108,472.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,462 shares of company stock worth $3,193,313. 2.13% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply